Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS401 in healthy volunteers with normal or mildly elevated triglycerides
NCT06041165Phase 1Unknown
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Aug 2023
- Primary completion
- Jun 2024
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hyperlipidemia comparing JS401 with Placebo (2 arms). Primary endpoint: Number of Participants with Adverse Events (AEs). Status: unknown.
02
Drugs
JSI-401
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT06041165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041165.